Publications by authors named "Naila Taguieva-Pioger"
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev
January 2024
Article Synopsis
- A systematic literature review was conducted to evaluate the effectiveness and safety of anti-VEGF treatments for patients with renal cell carcinoma (RCC) after they had previously received checkpoint inhibitor therapy.
- Out of 2,639 publications screened, 48 studies involving a total of 2,759 trial patients and 2,209 real-world study patients were deemed eligible, primarily focusing on the use of cabozantinib as an anti-VEGF therapy.
- The review found consistent evidence supporting anti-VEGF treatment efficacy after prior CPI therapy, with no new safety concerns identified, suggesting this may be a viable treatment option for RCC patients who have not responded to earlier therapies.
Cabozantinib is an inhibitor of multiple tyrosine kinases, including AXL, MET and VEGF receptors. Here, we describe the rationale and design for the phase II CaboPoint trial (ClinicalTrials.gov identifier: NCT03945773), which will evaluate the efficacy and safety of cabozantinib as a second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma whose disease has progressed despite checkpoint inhibitor therapy.
View Article and Find Full Text PDFObjectives: Erlotinib, an inhibitor of tyrosine kinase activity of the epidermal growth factor receptor, is effective in non-small cell lung cancer (NSCLC). Data on erlotinib use in squamous NSCLC are limited. This observational study aimed at evaluating the efficacy and safety of second-line erlotinib in patients with stage IIIB/IV squamous NSCLC in a real-life setting.
View Article and Find Full Text PDF